You are here: Home
Categories

PDE-5 Inhibitor:

1. Beyond the Abstract - Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: Modulation of nitric oxide mediated relaxation, by Cecil S. Thompson, PhD.
BERKELEY, CA (UroToday.com) - The corpus cavernosum exhibits biochemical and physiological properties similar to the vasculature; hence, considered by many to be a specialised blood vessel.
2. Beyond the Abstract - A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases, by Eric Chung
BERKELEY, CA (UroToday.com) - This review article examines the drug profile of vardenafil and its role in restoring erectile function; highlights a number of clinical trials on vardenafil in men with underlying ...
3. Beyond the Abstract - Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells, by Gayathri Chadalapaka, MD, et al.
BERKELEY, CA (UroToday.com) - The epidermal growth factor receptor (EGFR) and Sp (specificity protein) transcription factors (Sp1, Sp3 and Sp4) are overexpressed in many tumor types and are excellent targets ...
4. Beyond the Abstract - The future is today: Emerging drugs for the treatment of erectile dysfunction, by Maarten Albersen, MD
BERKELEY, CA (UroToday.com) - Erectile Dysfunction (ED) is the most common male sexual dysfunction presented for treatment, and the most thoroughly studied sexual dysfunction in men.
5. Beyond the Abstract - Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: A single center experience in 59 patients, by Philipp Ivanyi, MD and Viktor Grünwald, MD
BERKELEY, CA (UroToday.com) - Herein, the authors report on the development of a secondary hyperparathyroidism (sHPT) associated with tyrosine kinase inhibitor treatment, namely sunitinib and sorafenib, ...
6. Beyond the Abstract - Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma? by Sabine Brookman-May, MD
BERKELEY, CA (UroToday.com) - Recurrence rates of patients with localized and surgically treated renal cell carcinoma (RCC) range between 35-65%.
7. Beyond the Abstract - Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells, by Przemyslaw Twardowski, MD and C.A. Stein, MD, PhD
BERKELEY, CA (UroToday.com) - Androgen deprivation therapy for the management of advanced prostate cancer remains one of the most durable discoveries in medical oncology, and continues to undergo refinement ...
8. Treatment of mCRCP
The major biologic processes under therapeutic investigation in prostate cancer involve growth and survival, chemotherapy and hormone therapy resistance, extragonadal androgen production, modulation of ...
9. The impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades, "Beyond the Abstract," by In Ho Chang, MD, et al.
BERKELEY, CA (UroToday.com) - Our design of this abstract was to know how new medication therapy changed management of benign prostatic hyperplasia (BPH).
10. PDEI-5 for erectile dysfunction: A potential role in seizure susceptibility, "Beyond the Abstract," by Gabriela Matos, PhD, Sergio Tufik, MD, PhD, and Monica L. Andersen, PhD
BERKELEY, CA (UroToday.com) - Epilepsy is one of the most common chronic neurological diseases, affecting people of all ages and genders around the world.
11. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment, "Beyond the Abstract," by Tae Beom Kim, MD, et al.
BERKELEY, CA (UroToday.com) - Five α-reductase inhibitor (5ARI) is approved for the treatment of benign prostatic hyperplasia (BPH) and provides long-term symptom relief, increased urinary flow, and reduces ...
12. "Beyond the Abstract," The REDUCE metagram: A comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer, by Brandon K. Isariyawongse, MD and Michael W. Kattan, MBA, PhD
BERKELEY, CA (UroToday.com) - Evidence from both the Prostate Cancer Prevention Trial (PCPT) and the REDUCE trial has provided us with insight into the role of 5-alpha reductase inhibitors in chemoprevention ...
13. "Beyond the Abstract," Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: A RECORD-1 subgroup analysis, by Sergio Bracarda, MD
BERKELEY, CA (UroToday.com) - Drug Tolerability in the Choice of Second-Line Therapy for Metastatic Renal Cell Carcinoma
14. Initial and subsequent success with PDE5 inhibitor treatment for erectile dysfunction: Results of a pooled analysis of a large integrated clinical trial database, "Beyond the Abstract," by Angelina Sontag, PhD and Raymond Rosen, PhD
BERKELEY, CA (UroToday.com) - Erectile dysfunction (ED) affects a majority of men by the time they reach their 60s.[1]